Karimah Es Sabar Overview
- Company
- PHEMI Systems
- Primary Position
-
Board Member
- Primary Industry
-
Healthcare
- Active Board Seats
-
6
- Med. Deal Size
-
- Med. Valuation
-
Karimah Es Sabar General Information
Biography
Ms. Karimah Es Sabar serves as Board Member at PHEMI Systems. Ms. Es Sabar also served as Chief Executive Officer & General Partner at Quark Venture. She serves as a Board Member at GlycoNet, ARTMS Products, and Canary Medical. A highly-recognized Canadian life sciences leader with broad global experience, she has had a successful career spanning multi-national pharmaceutical/biotechnology companies, start-up companies, not-for-profit organizations, and venture investment firms. She has provided leadership in marketing, business development, strategic alliances, global collaborations, public-private partnerships, developing and executing innovation and translation strategies in the life science sector, and biotech investment. In July 2016, she accepted the position of CEO & Partner at Quark Venture Inc., a venture investment firm focused on life sciences investment, to expand and lead their health sciences enterprise. In partnership with leading Chinese private and public investment banks, one of the largest global health sciences venture funds will be headquartered in Vancouver, Canada with offices in Boston, Hong Kong, and Chengdu, to invest in North American and international companies. The fund is diversified to invest in disruptive pre-clinical and clinical-stage companies, IPOs, and publicly traded companies in the areas of drug development, vaccines, diagnostics, medical devices, health IT, and novel emerging convergent technologies. In 2009, she joined The Centre for Drug Research and Development, Canada's national drug development and commercialization center, as Senior Vice-President of Business and Strategic Affairs, leading its business functions and successfully building an array of national and international alliances and strategic industry partnerships. In 2012, she took on the role of President and CEO responsible for developing and executing the overall strategic direction of the organization. Since she joined CDRD, she enabled new public and private sector funding of over $180M, multiple commercial transactions including 6 spin-out companies and an M&A, and grew the organization with expanded national and international reach to include partnerships right across Canada and in 12 countries on five continents - firmly establishing its reputation as one of the world's leading pre-clinical translational research and commercialization centers. In this vein, she was also appointed Founding Chair of the Global Alliance of Leading Drug Discovery and Development Centres in 2013, an association of international peer organizations dedicated to translating health research into new medicines, the formation of which she spearheaded. She took on the role of leading BC Biotech in 2005, re-engineering and rebranding the organization to LifeSciences BC. As President, she led the organization to its greatest levels of success as a strong business development organization for the life science industry and the scientific research community. She holds a BS degree in Biochemistry & Chemistry from the University of Salford & also completed an MS degree in Neurochemistry from the University of London. He served as Board Member at Sitka Biopharma.
Contact Information
Address
- 777 Hornby Street
- Suite 600
- Vancouver, British Columbia V6Z 1S4
- Canada
Karimah Es Sabar Positions (1)
Firm name | Firm type | Title | Location | Industry | Since |
---|---|---|---|---|---|
Global Pharmaceutical Commercialization Center | Company | Chief Executive Officer | Chengdu, China | Pharmaceuticals |
Karimah Es Sabar Board Seats (6)
Company | Industry | Ownership Status | Financing Status | Location | Since |
---|---|---|---|---|---|
ARTMS | Other Devices and Supplies | Acquired/Merged (Operating Subsidiary) | Formerly VC-backed | Burnaby, Canada | |
Canary Medical | Medical Records Systems | Privately Held (backing) | Venture Capital-Backed | Carlsbad, CA | |
Capricor Therapeutics | Biotechnology | Publicly Held | Formerly VC-backed | San Diego, CA | |
GlycoNet | Edmonton, Canada | ||||
PHEMI Systems | Database Software | Privately Held (backing) | Venture Capital-Backed | Vancouver, Canada |
Karimah Es Sabar Lead Partner on Deals (13)
Karimah Es Sabar has been the lead partner on 13 deals. Their latest deal was with EyeYon Medical, a therapeutic devices company. The deal was made for on 15-Mar-2021.
Company | Deal Date | Deal Type | Deal Size | Deal Status | Industry | Location |
---|---|---|---|---|---|---|
EyeYon Medical | 15-Mar-2021 | Later Stage VC (Series C) | Completed | Therapeutic Devices | Ness Ziona, Israel | |
CalciMedica | 11-Mar-2021 | Completed | Drug Discovery | San Diego, CA | ||
V-Wave | 22-Sep-2020 | Completed | Therapeutic Devices | Caesarea, Israel | ||
ARTMS | 20-May-2020 | Completed | Other Devices and Supplies | Burnaby, Canada | ||
EnClear Therapies | 18-Feb-2020 | Completed | Therapeutic Devices | Newburyport, MA | ||
Sitka Biopharma | 11-Feb-2019 | Completed | Drug Delivery | Vancouver, Canada | ||
Canary Medical | 01-Jan-2019 | Completed | Medical Records Systems | Carlsbad, CA | ||
SQZ Biotech | 14-Aug-2018 | Completed | Drug Delivery | Watertown, MA | ||
Lyndra (China) Pharmaceuticals Company | 01-May-2018 | Joint Venture | Completed | Pharmaceuticals | Chengdu, China | |
Eloxx Pharmaceuticals | 02-Aug-2017 | Later Stage VC (Series C) | Completed | Biotechnology | Watertown, MA |
Karimah Es Sabar Network (167)
Board Members (44)
Name | Company | Representing | Location | From |
---|---|---|---|---|
Mike Satterfield | PHEMI Systems | Yaletown Partners | Vancouver, Canada | |
Khaled Emam Ph.D | Canary Medical | Self | Carlsbad, CA | |
PHEMI Systems | Self | Vancouver, Canada | ||
GlycoNet | Self | Edmonton, Canada | ||
ARTMS | Self | Burnaby, Canada |
Portfolio Executives (119)
Name | Company | Role | Deal date | Location |
---|---|---|---|---|
Arie Marcovich MD | EyeYon Medical | Co-Founder | 15-Mar-2021 | Ness Ziona, Israel |
Dmitry Dubson | EyeYon Medical | Chief Technology Officer & Vice President, Research & Development | 15-Mar-2021 | Ness Ziona, Israel |
EyeYon Medical | Co-Founder & Chief Executive Officer | 15-Mar-2021 | Ness Ziona, Israel | |
EyeYon Medical | Co-Founder & Medical Director | 15-Mar-2021 | Ness Ziona, Israel | |
EyeYon Medical | Head of Sales & Marketing | 15-Mar-2021 | Ness Ziona, Israel |
Fund Team Members (4)
Name | Investor | Fund | Fund Location |
---|---|---|---|
Zafrira Avnur Ph.D | GF Securities | Global Health Sciences Fund | Guangzhou, China |
Zafrira Avnur Ph.D | Quark Venture | Global Health Sciences Fund | Vancouver, Canada |
GF Securities | Guangzhou, China | ||
Quark Venture | Vancouver, Canada | ||
GF Securities | Guangzhou, China |
Karimah Es Sabar Affiliated Funds (1)
Fund | Investor | Fund Type | Status | Vintage | Size | Dry Powder | IRR | IRR Quartile |
---|---|---|---|---|---|---|---|---|
Global Health Sciences Fund | GF Securities | Venture - General | Closed | 2016 |
Karimah Es Sabar FAQs
-
Who is Karimah Es Sabar?
Ms. Karimah Es Sabar serves as Board Member at PHEMI Systems.
-
How much does Karimah Es Sabar typically invest?
Karimah Es Sabar's median deal size is
. -
What is Karimah Es Sabar’s main position?
Karimah Es Sabar’s primary position is Board Member.
-
How many active board seats does Karimah Es Sabar hold?
Karimah Es Sabar holds 6 board seats including ARTMS, Canary Medical, Capricor Therapeutics, GlycoNet, and PHEMI Systems.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »